Correlation between myocardial fibrosis and restrictive cardiac physiology in patients undergoing retransplantation

Clinical Transplantation

Volumn 27, Issue 6, 2013, Pages

  Kobashigawa, Jon A ^a   Itagaki, Brandon K ^b   Razi, Rabia R ^a   Patel, Jignesh K ^a   Chai, Wanxing ^a   Kawano, Matthew A ^a   Goldstein, Zachary ^a   Kittleson, Michelle M ^a   Fishbein, Michael C ^c  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b KAISER PERMANENTE   (United States)

^c UCLA MEDICAL CENTER   (United States)

Author keywords

Cardiac allograft vasculopathy; Inflammation; Myocardial fibrosis; Restrictive cardiac physiology; Retransplantation

Indexed keywords

ADULT; ARTICLE; CLINICAL ARTICLE; CORRELATION ANALYSIS; FEMALE; HEART DISEASE; HEART MUSCLE FIBROSIS; HEART TRANSPLANTATION; HEMODYNAMICS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; MEDICAL HISTORY; PRIORITY JOURNAL; RETRANSPLANTATION; RETROSPECTIVE STUDY;

CARDIAC ALLOGRAFT VASCULOPATHY; INFLAMMATION; MYOCARDIAL FIBROSIS; RESTRICTIVE CARDIAC PHYSIOLOGY; RETRANSPLANTATION;

ADULT; CARDIOMYOPATHY, RESTRICTIVE; FEMALE; FIBROSIS; FOLLOW-UP STUDIES; GRAFT REJECTION; HEART FAILURE; HEART TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MYOCARDIUM; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; REOPERATION; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84889098093     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/ctr.12250     Document Type: Article

References (31)

1. Srivastava R, Keck BM, Bennett LE, Hosenpud JD. The results of cardiac retransplantation: an analysis of the Joint International Society for Heart and Lung Transplantation/United Network for Organ Sharing Thoracic Registry. Transplantation 2000: 70: 606.
2. Topkara VK, Dang NC, John R et al. A decade experience of cardiac retransplantation in adult recipients. J Heart Lung Transplant 2005: 24: 1745.
3. Mocumbi AO, Latif N, Yacoub MH. Presence of circulating anti-myosin antibodies in endomyocardial fibrosis. PLoS Negl Trop Dis 2010: 4: e661.
4. Moreo A, Ambrosio G, De Chiara B et al. Influence of myocardial fibrosis on left ventricular diastolic function: noninvasive assessment by cardiac magnetic resonance and echo. Circ Cardiovasc Imaging 2009: 2: 437.
5. Sliwa K, Damasceno A, Mayosi BM. Epidemiology and etiology of cardiomyopathy in Africa. Circulation 2005: 112: 3577.
6. Gramley F, Lorenzen J, Pezzella F et al. Hypoxia and myocardial remodeling in human cardiac allografts: a time-course study. J Heart Lung Transplant 2009: 28: 1119.
7. Armstrong AT, Binkley PF, Baker PB, Myerowitz PD, Leier CV. Quantitative investigation of cardiomyocyte hypertrophy and myocardial fibrosis over 6 years after cardiac transplantation. J Am Coll Cardiol 1998: 32: 704.
8. Perens G, Li F, Meier S, Kaur R, Alejos JC, Fishbein M. Clinico-pathologic findings in end-stage pediatric heart transplant grafts. Pediatric Transplant 2009: 13: 887.
9. Billingham ME, Cary NR, Hammond ME et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group. The International Society for Heart Transplantation. J Heart Transplant 1990: 9: 587.
10. Giannuzzi P, Temporelli PL, Bosimini E et al. Independent and incremental prognostic value of Doppler-derived mitral deceleration time of early filling in both symptomatic and asymptomatic patients with left ventricular dysfunction. J Am Coll Cardiol 1996: 28: 383.
11. Oh JK, Seward JB, Tajik AJ. The Echo Manual, 2nd edn. Philadelphia: Lippincott-Raven, 1999.
12. Xie GY, Berk MR, Smith MD, Gurley JC, DeMaria AN. Prognostic value of Doppler transmitral flow patterns in patients with congestive heart failure. J Am Coll Cardiol 1994: 24: 132.
13. Lu WH, Palatnik K, Fishbein GA et al. Diverse morphologic manifestations of cardiac allograft vasculopathy: a pathologic study of 64 allograft hearts. J Heart Lung Transplant. 2011: 30: 1044.
14. Franz M, Grun K, Richter P et al. Extra cellular matrix remodelling after heterotopic rat heart transplantation: gene expression profiling and involvement of ED-A+ fibronectin, alpha-smooth muscle actin and B+ tenascin-C in chronic cardiac allograft rejection. Histochem Cell Biol 2010: 134: 503.
15. Diaz JA, Booth AJ, Lu G, Wood SC, Pinsky DJ, Bishop DK. Critical role for IL-6 in hypertrophy and fibrosis in chronic cardiac allograft rejection. Am J Transplant 2009: 9: 1773.
16. Law Y, Boyle G, Miller S et al. Restrictive hemodynamics are present at the time of diagnosis of allograft coronary artery disease in children. Pediatr Transplant 2006: 10: 948.
17. Billingham ME. Cardiac transplant atherosclerosis. Transpl Proc 1987: 19(4 Suppl. 5): 19.
18. Deng MC, Plenz G, Erren M et al. Transplant vasculopathy: a model for coronary artery disease? Herz. 2000: 25: 95.
19. Hiemann NE, Wellnhofer E, Bocksch W, Hetzer R. Relationship between angiographic graft vessel disease and microvascular reaction after heart transplantation. Int J Angiol 2002: 11: 225.
20. Clausell N, Butany J, Molossi S et al. Abnormalities in intramyocardial arteries detected in cardiac transplant biopsy specimens and lack of correlation with abnormal intracoronary ultrasound or endothelial dysfunction in large epicardial coronary arteries. J Am Coll Cardiol 1995: 26: 110.
21. Ardehali A, Laks H, Drinkwater DC Jr. et al. Expression of major histocompatibility antigens and vascular adhesion molecules on human cardiac allografts preserved in University of Wisconsin solution. J Heart Lung Transplant 1993: 12: 1044; discussion 51-2.
22. Gao HZ, Hunt SA, Alderman EL, Liang D, Yeung AC, Schroeder JS. Relation of donor age and preexisting coronary artery disease on angiography and intracoronary ultrasound to later development of accelerated allograft coronary artery disease. J Am Coll Cardiol 1997: 29: 623.
23. Hosenpud JD. Coronary artery disease after heart transplantation and its relation to cytomegalovirus. Am Heart J 1999: 138: S469.
24. Uretsky BF, Murali S, Reddy PS et al. Development of coronary artery disease in cardiac transplant patients receiving immunosuppressive therapy with cyclosporine and prednisone. Circulation 1987: 76: 827.
25. Winters GL, Kendall TJ, Radio SJ et al. Posttransplant obesity and hyperlipidemia: major predictors of severity of coronary arteriopathy in failed human heart allografts. J Heart Transplant 1990: 9: 364.
26. Hiemann NE, Wellnhofer E, Hetzer R, Meyer R. Small vessel disease after heart transplantation: impact of immunologic and nonimmunologic risk factors. Transpl Int 2005: 18: 908.
27. Palmer DC, Tsai CC, Roodman ST et al. Heart graft arteriosclerosis. An ominous finding on endomyocardial biopsy. Transplantation 1985: 39: 385.
28. Perens G, Li F, Meier S, Kaur R, Alejos JC, Fishbein M. Clinico-pathologic findings in end-stage pediatric heart transplant grafts. Pediatr Transplant 2009: 13: 887.
29. Yamani MH, Haji SA, Starling RC et al. Myocardial ischemic-fibrotic injury after human heart transplantation is associated with increased progression of vasculopathy, decreased cellular rejection and poor long-term outcome. J Am Coll Cardiol 2002: 39: 970.
30. Di Bella G, Minutoli F, Coglitore S et al. Cardiac allograft vasculopathy: complications and imaging studies. Herz 2011: 36: 630.
31. Whalley GA, Gamble GD, Doughty RN. The prognostic significance of restrictive diastolic filling associated with heart failure: a meta-analysis. Int J Cardiol 2007: 116: 70.